Any current/future new fundraising through debt or equity?

The document does not explicitly mention any current or upcoming fundraising plans through debt or equity. Capex plans for FY24 and FY25 are detailed (INR 160 crores in FY24 and around INR 200-220 crores in FY25), funded likely through internal resources and cash investments (INR 237 crores as of December 31). No specific mention of raising funds via equity or debt in the Q3 FY24 earnings call or in management comments. Focus appears to be on utilizing cash balances and project-specific investments rather than external fundraising currently. Any future capital raises, if planned, are n

Any current/future capex/capital investment/strategic investment?

Mahad site: INR 250 crores capex split between FY24 and FY25; includes two blocks: - Backward integration block for raw materials (planned completion by Q3 FY25) - Multiproduct intermediate block for CDMO opportunities (cardiovascular, CNS, oncology) - Significant portion allocated to utilities and infrastructure upgrades Ambernath Unit 2: INR 90-100 crores capex nearly complete by March-April 2024; capacity ready for validation in Q1 FY25 Greenfield site: EC application in progress; accelerated investments expected, with facility operational by FY26 Solar project: INR 30 crores invested

Future growth expectations in sales/revenue/volumes?

Contrast media business is expected to see growth from Q2/Q3 FY25 with approvals and marketing efforts stabilizing in the US and Europe. New contrast media product validation expected this quarter, with commercial volumes ramping up from Q2/Q3 FY25. Pharmaceutical intermediate (PI API) segment, particularly for the cardiovascular drug with patent protection till 2030, is projected to grow significantly with commercial capacity increasing from Q1 FY25. Artificial sweetener business faces short-term challenges due to Chinese dumping; focus is shifting to long-term CDMO customers, new sweet

Future growth expectations in earnings/operating earnings/profits/EPS?

Blue Jet Healthcare expects a conservative growth outlook with room for aggressive catch-up post capex stabilization, particularly from backward integration efforts (Page 16). Gross margins are projected to sustain around 57%-58% for a couple of quarters but may normalize closer to 55% medium-term due to product mix and integration dynamics (Pages 14-15). Pharma Intermediate (PI) segment grew 250% in Q3 FY24, with ambitions to increase 10x-15x over 2-3 years, driven by high-value NCE intermediates like Espiron (Pages 5, 6, 9-11). Contrast media business is expected to ramp up from Q2 FY25 o

Current/ Expected Orderbook/ Pending Orders?

Blue Jet Healthcare did not explicitly mention current or expected order book values or pending orders in the transcript. They highlighted ongoing supply contracts, notably being a primary supplier of key pharmaceutical intermediates like Espiron and contrast media intermediates. The company mentioned aggressive ramp-ups and validated new products expected to drive strong revenue growth from Q2/Q3 FY 2025. There are long-term supply agreements with customers, though no guaranteed volumes are disclosed. The business is focused on increasing contractual revenues, expanding wallet share with exis

Blue Jet HealthQ3 FY24Pharmaceuticals & Biotechnology

Blue Jet Health Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹542P/E: 46.0Market Cap: ₹10.8K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 4

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Contrast media business is expected to see growth from Q2/Q3 FY25 with approvals and marketing efforts stabilizing in the US and Europe.
New contrast media product validation expected this quarter, with commercial volumes ramping up from Q2/Q3 FY25.
Pharmaceutical intermediate (PI API) segment, particularly for the cardiovascular drug with patent protection till 2030, is projected to grow significantly with commercial capacity increasing from Q1 FY25.
Artificial sweetener business faces short-term challenges due to Chinese dumping; focus is shifting to long-term CDMO customers, new sweeteners, and expanding customer base for recovery over 12-18 months.
Backward integration and capex in Mahad and Ambernath units are expected to provide stability and support growth in advanced intermediates and CDMO opportunities.
Conservative revenue growth estimates are maintained with potential for aggressive catch-up post-capex stabilization.
Overall, medium-term revenue growth is anticipated with capacity ramp-ups and product launches aligned to FY25 and FY26 timelines.

Margin guidance

Category 4

Blue Jet Healthcare expects a conservative growth outlook with room for aggressive catch-up post capex stabilization, particularly from backward integration efforts (Page 16).
Gross margins are projected to sustain around 57%-58% for a couple of quarters but may normalize closer to 55% medium-term due to product mix and integration dynamics (Pages 14-15).
Pharma Intermediate (PI) segment grew 250% in Q3 FY24, with ambitions to increase 10x-15x over 2-3 years, driven by high-value NCE intermediates like Espiron (Pages 5, 6, 9-11).
Contrast media business is expected to ramp up from Q2 FY25 onwards, with new product validations and label expansions driving volume growth (Pages 5, 10-11).
Artificial sweetener business recovery is planned over 12-18 months through addition of new sweeteners and focusing on long-term CDMO customers (Page 15).
Capex of INR160 crores expected in FY24 and INR200-220 crores in FY25 to support capacity expansion and backward integration (Page 11).
Overall, growth driven by expanding CDMO services in pharma intermediates and contrast media, with cautious margin and capex management.

See what Blue Jet Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

The document does not explicitly mention any current or upcoming fundraising plans through debt or equity.
Capex plans for FY24 and FY25 are detailed (INR 160 crores in FY24 and around INR 200-220 crores in FY25), funded likely through internal resources and cash investments (INR 237 crores as of December 31).
No specific mention of raising funds via equity or debt in the Q3 FY24 earnings call or in management comments.
Focus appears to be on utilizing cash balances and project-specific investments rather than external fundraising currently.
Any future capital raises, if planned, are not disclosed in the provided content from this earnings call.

Order book

Blue Jet Healthcare did not explicitly mention current or expected order book values or pending orders in the transcript.
They highlighted ongoing supply contracts, notably being a primary supplier of key pharmaceutical intermediates like Espiron and contrast media intermediates.
The company mentioned aggressive ramp-ups and validated new products expected to drive strong revenue growth from Q2/Q3 FY 2025.
There are long-term supply agreements with customers, though no guaranteed volumes are disclosed.
The business is focused on increasing contractual revenues, expanding wallet share with existing customers, and adding new clients, particularly for artificial sweeteners and advanced intermediates.
Capex plans indicate investment capacity expansion, suggesting expected order growth, but specific order book figures were not provided.

See what Blue Jet Health management said on order book — free account, 30 seconds.

Capex plans

Yes

Mahad site: INR 250 crores capex split between FY24 and FY25; includes two blocks:
- Backward integration block for raw materials (planned completion by Q3 FY25)
- Multiproduct intermediate block for CDMO opportunities (cardiovascular, CNS, oncology)
- Significant portion allocated to utilities and infrastructure upgrades
Ambernath Unit 2: INR 90-100 crores capex nearly complete by March-April 2024; capacity ready for validation in Q1 FY25
Greenfield site: EC application in progress; accelerated investments expected, with facility operational by FY26
Solar project: INR 30 crores invested; over 60% of power requirement expected from renewable sources for cost savings
Continued R&D expansion to support pipeline growth in contrast media, pharma intermediates, and artificial sweeteners

Track Blue Jet Health — get its next earnings analysis in your feed

How does Blue Jet Health rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisBlue Jet Health

Rev 3Mar 4

See where Blue Jet Health sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Blue Jet Health rank in Pharmaceuticals & Biotechnology?

Compare Blue Jet Health against every Pharmaceuticals & Biotechnology company (Q3 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Blue Jet Health's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →